Compliance and toxicity in metastatic colorectal carcinoma patients treated with capecitabine versus 5-FU associated with oxaliplatin or irinotecan

被引：0
|
作者：
Raimondi, C. [1 ]
Longo, F. [1 ]
Tomao, S. [1 ]
Ricciardi, S. [1 ]
Rosati, S. [1 ]
Messina, C. G. M. [1 ]
Cerbone, L. [1 ]
Spalletta, B. [1 ]
Russillo, M. [1 ]
Di Seri, M. [1 ]
机构：
[1] Policlin Umberto 1, UOC Oncol A, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI43 / XI43
页数：1
相关论文
共 50 条
  • [1] Capecitabine versus 5FU in association with oxaliplatin or CPT11 in metastatic colorectal carcinoma (MCRC) patients: Compliance and toxicity
    Di Seri, M.
    Ricciardi, S.
    Messina, C.
    Rossi, L.
    Rosati, S.
    Spalletta, B.
    Cerbone, L.
    Russillo, M.
    Manna, A.
    Iongo, F.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 69 - 69
  • [2] CAPECITABINE VERSUS 5-FU IN ASSOCIATION WITH OXALIPLATIN OR CPT11: TOXICITY AND PATIENT COMPLIANCE
    Spalletta, B.
    Tomao, S.
    Manna, A.
    Santini, D.
    Longo, F.
    Coletta, D.
    Petricola, F.
    Proietti, E.
    Borgomastro, A.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 69 - 69
  • [3] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
    Amoroso, Vito
    Ferrari, Vittorio
    Valcamonico, Francesca
    Vassalli, Lucia
    Simoncini, Edda
    Grisanti, Salvatore
    Marpicati, Patrizia
    Rangoni, Giovanni
    Marini, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
  • [4] Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin (CIFOX).
    Agafitei, RD
    Schneider, S
    Iqbal, S
    Yang, D
    Groshen, S
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
  • [5] A phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU versus the Leucovorin Calcium followed by 5-FU both in combination with Irinotecan or Oxaliplatin in patients with metastatic colorectal cancer
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezaei
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    [J]. ACTA GASTRO-ENTEROLOGICA BELGICA, 2012, 75 (01): : 14 - 21
  • [6] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
    Guo, Yuanbiao
    Shi, Min
    Shen, Xiaoheng
    Yang, Chen
    Yang, Liu
    Zhang, Jun
    [J]. CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
  • [7] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    J B Kjersem
    M Thomsen
    T Guren
    J Hamfjord
    G Carlsson
    B Gustavsson
    T Ikdahl
    G Indrebø
    P Pfeiffer
    O Lingjærde
    K M Tveit
    Y Wettergren
    E H Kure
    [J]. The Pharmacogenomics Journal, 2016, 16 : 272 - 279
  • [8] AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
    Kjersem, J. B.
    Thomsen, M.
    Guren, T.
    Hamfjord, J.
    Carlsson, G.
    Gustavsson, B.
    Ikdahl, T.
    Indrebo, G.
    Pfeiffer, P.
    Lingjaerde, O.
    Tveit, K. M.
    Wettergren, Y.
    Kure, E. H.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (03): : 272 - 279
  • [9] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.
    Yun, J
    Zhang, W
    Park, D
    Yang, D
    Press, O
    Gordon, M
    Mallik, N
    Lenz, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 249S - 249S
12345